Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 16/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350449 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL29350915 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL4662734 | 0.96 | EGFR (0.92) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL30115314 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL2985038 | 0.88 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL30115332 | 0.88 | EGFR (0.84) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL7208931 | 0.88 | EGFR (0.78) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL30115348 | 0.87 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL30115365 | 0.87 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL12012727 | 0.87 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 987 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207805-B1 | NLRR-1 ANTAGONISTS AND USES THEREOF | GENENTECH INC (US) | 2014-07-09 | — | — | EP | claimed |
| EP-1553950-B1 | THERAPEUTIC TREATMENT | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | claimed |
| EP-1202746-B1 | NSAID AND EGFR KINASE INHIBITOR CONTAINING COMPOSITION FOR THE TREATMENT OR INHIBITION OF COLONIC POLYPS AND COLORECTAL CANCER | WYETH CORP (US) | 2006-10-04 | — | — | EP | claimed |
| US-20060122180-A1 | Therapeutic treatment | BOYLE FRANCIS T | 2006-06-08 | — | — | US | claimed |
| EP-1553950-A1 | THERAPEUTIC TREATMENT | Astrazeneca AB (SE) | 2005-07-20 | — | — | EP | claimed |
| WO-2004035057-A1 | THERAPEUTIC TREATMENT | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | WO | claimed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| EP-0980244-B1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH CORP (US) | 2003-06-04 | — | — | EP | claimed |
| EP-1202746-A1 | NSAID AND EFGR KINASE INHIBITOR CONTAINING COMPOSITION FOR THE TREATMENT OR INHIBITION OF COLONIC POLYPS AND COLORECTAL CANCER | American Cyanamid Company (US) | 2002-05-08 | — | — | EP | claimed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2001012227-A1 | NSAID AND EFGR KINASE INHIBITOR CONTAINING COMPOSITION FOR THE TREATMENT OR INHIBITION OF COLONIC POLYPS AND COLORECTAL CANCER | AMERICAN CYANAMID COMPANY (US) | 2001-02-22 | — | — | WO | claimed |
| EP-1039910-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | American Cyanamid Company (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0980244-A1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | American Cyanamid Company (US) | 2000-02-23 | — | — | EP | claimed |
| US-5929080-A | ADMINISTERING PHENYLAMINOQUINAZOLINE DERIVATIVE | AMERICAN CYANAMID COMPANY (US) | 1999-07-27 | — | — | US | claimed |
| WO-1999024037-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 1999-05-20 | — | — | WO | claimed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1998050038-A1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY (US) | 1998-11-12 | — | — | WO | claimed |
| US-5760041-A | 4-aminoquinazoline EGFR Inhibitors | AMERICAN CYANAMID COMPANY (US) | 1998-06-02 | — | — | US | claimed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | claimed |
| EP-0787722-A1 | Substituted quinazoline derivatives | American Cyanamid Company (US) | 1997-08-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885ERBB4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.